cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.23884506
title: Supplementary Material for: Cardiac troponin T and NT-proBNP for prediction of 30-day readmission or death in patients with acute dyspnea: Data from the Akershus Cardiac Examination 2 Study

description: Introduction: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) measurements are recommended in patients with acute dyspnea. We aimed to assess the prognostic merit of cTnT compared to NT-proBNP for 30-day readmission or death in patients hospitalized with acute dyspnea. Methods: We measured cTnT and NT-proBNP within 24 hours in 314 patients hospitalized with acute dyspnea and adjudicated the cause of the index admission. Time to first event of readmission or death ≤30 days after hospital discharge was recorded and cTnT and NT-proBNP measurements were compared head-to-head. Results: Five patients died during the index admission and were excluded from the study. Patients who died (7/309) or were readmitted (71/309) within 30 days had higher cTnT concentrations (median 29.1, Q1-Q3 18.2-73.9 ng/L) compared to patient who survived and were not readmitted (median 19.4, Q1-Q3 8.4-36.1 ng/L; p &lt;0.001). There were no statistically significant differences in NT proBNP concentrations when stratifying patients according to readmission or death within 30 days: median 1540.6, Q1-Q3 424-5571 ng/L vs. median 984, Q1-Q3 201-3600 (p = 0.07). cTnT concentrations separated patients with poor and favorable outcomes, both for the total cohort and for patients with adjudicated heart failure (HF). cTnT concentrations were associated with readmission or death within 30 days after discharge, both in the total cohort (adjusted hazard ratio [aHR] 1.65, 95% CI 1.30-2.08) and in patients with HF (aHR 1.60, 95% CI 1.15-2.24). In contrast, NT-proBNP concentrations were not associated with prognosis in the total cohort (aHR 1.11, 95% CI 0.94-1.31) or in patients with adjudicated HF (aHR 1.03, 95% CI 0.78-1.37). In the subgroup analysis of HF patients, where patients with acute HF were grouped according to LVEF (HFpEF and HFrEF), cTnT and NT proBNP did not predict short-term outcomes for HFrEF, but cTnT predicted short-term outcomes in HFpEF patients. Conclusions: cTnT concentrations associate with post-discharge 30-day readmission or death in patients hospitalized with acute dyspnea, as well as in in patients adjudicated HF. The association of cTnT with outcomes in HF appears driven by strong associations of cTnT in patients with HFpEF.
DOI: 10.6084/m9.figshare.23884506.v1
title: Supplementary Material for: Cardiac troponin T and NT-proBNP for prediction of 30-day readmission or death in patients with acute dyspnea: Data from the Akershus Cardiac Examination 2 Study

description: Introduction: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) measurements are recommended in patients with acute dyspnea. We aimed to assess the prognostic merit of cTnT compared to NT-proBNP for 30-day readmission or death in patients hospitalized with acute dyspnea. Methods: We measured cTnT and NT-proBNP within 24 hours in 314 patients hospitalized with acute dyspnea and adjudicated the cause of the index admission. Time to first event of readmission or death ≤30 days after hospital discharge was recorded and cTnT and NT-proBNP measurements were compared head-to-head. Results: Five patients died during the index admission and were excluded from the study. Patients who died (7/309) or were readmitted (71/309) within 30 days had higher cTnT concentrations (median 29.1, Q1-Q3 18.2-73.9 ng/L) compared to patient who survived and were not readmitted (median 19.4, Q1-Q3 8.4-36.1 ng/L; p &lt;0.001). There were no statistically significant differences in NT proBNP concentrations when stratifying patients according to readmission or death within 30 days: median 1540.6, Q1-Q3 424-5571 ng/L vs. median 984, Q1-Q3 201-3600 (p = 0.07). cTnT concentrations separated patients with poor and favorable outcomes, both for the total cohort and for patients with adjudicated heart failure (HF). cTnT concentrations were associated with readmission or death within 30 days after discharge, both in the total cohort (adjusted hazard ratio [aHR] 1.65, 95% CI 1.30-2.08) and in patients with HF (aHR 1.60, 95% CI 1.15-2.24). In contrast, NT-proBNP concentrations were not associated with prognosis in the total cohort (aHR 1.11, 95% CI 0.94-1.31) or in patients with adjudicated HF (aHR 1.03, 95% CI 0.78-1.37). In the subgroup analysis of HF patients, where patients with acute HF were grouped according to LVEF (HFpEF and HFrEF), cTnT and NT proBNP did not predict short-term outcomes for HFrEF, but cTnT predicted short-term outcomes in HFpEF patients. Conclusions: cTnT concentrations associate with post-discharge 30-day readmission or death in patients hospitalized with acute dyspnea, as well as in in patients adjudicated HF. The association of cTnT with outcomes in HF appears driven by strong associations of cTnT in patients with HFpEF.
DOI: 10.6084/m9.figshare.23884509
title: Supplementary Material for: Cardiac troponin T and NT-proBNP for prediction of 30-day readmission or death in patients with acute dyspnea: Data from the Akershus Cardiac Examination 2 Study

description: Introduction: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) measurements are recommended in patients with acute dyspnea. We aimed to assess the prognostic merit of cTnT compared to NT-proBNP for 30-day readmission or death in patients hospitalized with acute dyspnea. Methods: We measured cTnT and NT-proBNP within 24 hours in 314 patients hospitalized with acute dyspnea and adjudicated the cause of the index admission. Time to first event of readmission or death ≤30 days after hospital discharge was recorded and cTnT and NT-proBNP measurements were compared head-to-head. Results: Five patients died during the index admission and were excluded from the study. Patients who died (7/309) or were readmitted (71/309) within 30 days had higher cTnT concentrations (median 29.1, Q1-Q3 18.2-73.9 ng/L) compared to patient who survived and were not readmitted (median 19.4, Q1-Q3 8.4-36.1 ng/L; p &lt;0.001). There were no statistically significant differences in NT proBNP concentrations when stratifying patients according to readmission or death within 30 days: median 1540.6, Q1-Q3 424-5571 ng/L vs. median 984, Q1-Q3 201-3600 (p = 0.07). cTnT concentrations separated patients with poor and favorable outcomes, both for the total cohort and for patients with adjudicated heart failure (HF). cTnT concentrations were associated with readmission or death within 30 days after discharge, both in the total cohort (adjusted hazard ratio [aHR] 1.65, 95% CI 1.30-2.08) and in patients with HF (aHR 1.60, 95% CI 1.15-2.24). In contrast, NT-proBNP concentrations were not associated with prognosis in the total cohort (aHR 1.11, 95% CI 0.94-1.31) or in patients with adjudicated HF (aHR 1.03, 95% CI 0.78-1.37). In the subgroup analysis of HF patients, where patients with acute HF were grouped according to LVEF (HFpEF and HFrEF), cTnT and NT proBNP did not predict short-term outcomes for HFrEF, but cTnT predicted short-term outcomes in HFpEF patients. Conclusions: cTnT concentrations associate with post-discharge 30-day readmission or death in patients hospitalized with acute dyspnea, as well as in in patients adjudicated HF. The association of cTnT with outcomes in HF appears driven by strong associations of cTnT in patients with HFpEF.
DOI: 10.6084/m9.figshare.23884509.v1
title: Supplementary Material for: Cardiac troponin T and NT-proBNP for prediction of 30-day readmission or death in patients with acute dyspnea: Data from the Akershus Cardiac Examination 2 Study

description: Introduction: N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) measurements are recommended in patients with acute dyspnea. We aimed to assess the prognostic merit of cTnT compared to NT-proBNP for 30-day readmission or death in patients hospitalized with acute dyspnea. Methods: We measured cTnT and NT-proBNP within 24 hours in 314 patients hospitalized with acute dyspnea and adjudicated the cause of the index admission. Time to first event of readmission or death ≤30 days after hospital discharge was recorded and cTnT and NT-proBNP measurements were compared head-to-head. Results: Five patients died during the index admission and were excluded from the study. Patients who died (7/309) or were readmitted (71/309) within 30 days had higher cTnT concentrations (median 29.1, Q1-Q3 18.2-73.9 ng/L) compared to patient who survived and were not readmitted (median 19.4, Q1-Q3 8.4-36.1 ng/L; p &lt;0.001). There were no statistically significant differences in NT proBNP concentrations when stratifying patients according to readmission or death within 30 days: median 1540.6, Q1-Q3 424-5571 ng/L vs. median 984, Q1-Q3 201-3600 (p = 0.07). cTnT concentrations separated patients with poor and favorable outcomes, both for the total cohort and for patients with adjudicated heart failure (HF). cTnT concentrations were associated with readmission or death within 30 days after discharge, both in the total cohort (adjusted hazard ratio [aHR] 1.65, 95% CI 1.30-2.08) and in patients with HF (aHR 1.60, 95% CI 1.15-2.24). In contrast, NT-proBNP concentrations were not associated with prognosis in the total cohort (aHR 1.11, 95% CI 0.94-1.31) or in patients with adjudicated HF (aHR 1.03, 95% CI 0.78-1.37). In the subgroup analysis of HF patients, where patients with acute HF were grouped according to LVEF (HFpEF and HFrEF), cTnT and NT proBNP did not predict short-term outcomes for HFrEF, but cTnT predicted short-term outcomes in HFpEF patients. Conclusions: cTnT concentrations associate with post-discharge 30-day readmission or death in patients hospitalized with acute dyspnea, as well as in in patients adjudicated HF. The association of cTnT with outcomes in HF appears driven by strong associations of cTnT in patients with HFpEF.
DOI: 10.34740/kaggle/dsv/6251314
title:  OpenAssistant-oasst1-fa
DOI: 10.3886/e193128v1
title: ESG alpha research data from 2000 to 2022

description: Five small files contain daily index data for volatility and implied volatility of EURO STOXX 50, EURO STOXX 600 (only volatility data) and FTSE 100. This was collected from Refinitiv EIKON.<br><br>The large file contains ESG ratings of all European companies, and the adjusted daily prices of most of these companies. The ESG ratings were collected from Refinitiv EIKON. The adjusted daily prices were collected from Yahoo Finance!.
description: All stocks with ESG ratings
description: Europe.
DOI: 10.34740/kaggle/dsv/6251328
title:  OpenAssistant-oasst1-fa
DOI: 10.6084/m9.figshare.23884263
title: Untitled Item

description: NHDPlus raw data
DOI: 10.6084/m9.figshare.23884263.v1
title: Untitled Item

description: NHDPlus raw data
DOI: 10.34740/kaggle/dsv/6251342
title:  OpenAssistant-oasst1-fa
DOI: 10.5281/zenodo.8216637
title: Improving the mating competitiveness of male Anastrepha ludens (Diptera: Tephritidae) fruit flies by adding two juvenile hormone analogues

description: Improving the mating competitiveness and survival of sterile males are direct means to increasing the effectiveness of the Sterile Insect Technique (SIT). Some insecticide growth regulators, such as the juvenile hormone analogue (JHA) Methoprene, have been used to improve the mating competitiveness of male tephritid flies by reducing their sexual maturation period. However, a decrease in the period of sexual maturation induces a reduction in survival. Here, we compared the effects of methoprene and Pyriproxyfen (PPF), another JHA, in <em>Anastrepha</em> <em>ludens</em> males. Pyriproxyfen is an insect growth regulator that exhibits higher disruption on insects’ methamorphosis than methoprene or than natural JH. . Both compounds were administered at two doses (0.05 and 0.1%) via the male diet immediately after emergence. Our results show that both Pyriproxyfen and methoprene reduced male sexual maturation. However, PPF-treated males exhibited a shorter maturation period and obtained more matings at a given age than methoprene-treated males . No significant differences were observed between the two PPF doses tested (0.05 and 0.10 %). Male survival was equally accelerated by the two compounds. Our results demonstrate that PPF can be used as a tool to improve the mating performance of sterile males.
DOI: 10.5281/zenodo.8216636
title: Improving the mating competitiveness of male Anastrepha ludens (Diptera: Tephritidae) fruit flies by adding two juvenile hormone analogues

description: Improving the mating competitiveness and survival of sterile males are direct means to increasing the effectiveness of the Sterile Insect Technique (SIT). Some insecticide growth regulators, such as the juvenile hormone analogue (JHA) Methoprene, have been used to improve the mating competitiveness of male tephritid flies by reducing their sexual maturation period. However, a decrease in the period of sexual maturation induces a reduction in survival. Here, we compared the effects of methoprene and Pyriproxyfen (PPF), another JHA, in <em>Anastrepha</em> <em>ludens</em> males. Pyriproxyfen is an insect growth regulator that exhibits higher disruption on insects’ methamorphosis than methoprene or than natural JH. . Both compounds were administered at two doses (0.05 and 0.1%) via the male diet immediately after emergence. Our results show that both Pyriproxyfen and methoprene reduced male sexual maturation. However, PPF-treated males exhibited a shorter maturation period and obtained more matings at a given age than methoprene-treated males . No significant differences were observed between the two PPF doses tested (0.05 and 0.10 %). Male survival was equally accelerated by the two compounds. Our results demonstrate that PPF can be used as a tool to improve the mating performance of sterile males.
DOI: 10.34740/kaggle/dsv/6251358
title:  OpenAssistant-oasst1-fa
DOI: 10.34740/kaggle/dsv/6251365
title:  OpenAssistant-oasst1-fa
DOI: 10.6084/m9.figshare.23884521.v1
title: Supplementary Material for: Validation of administrative health data algorithms for identifying persons with Parkinson’s disease and the ten-year prevalence trend in Bologna, Italy

description: Introduction Health administrative databases are widely used for the estimation of the prevalence of Parkinson’s Disease (PD). Few in general, and none used in Italy, have been validated by testing their diagnostic accuracy. The primary objective was to validate two algorithms for the identification of persons with PD using clinical diagnosis as the reference standard on an Italian sample of people with PD. The second objective was to estimate 10-year trends in PD prevalence in the Bologna Local Health Trust from 2010 to 2019. Methods Two algorithms (index tests) applied to health administrative databases (hospital discharge, drug prescriptions, exemptions for medical costs) were validated against clinical diagnosis of PD by an expert neurologist (reference standard) in a cohort of consecutive outpatients. Sensitivity and specificity with relative 95% confidence intervals (CI) were calculated. The prevalence of PD in a specific year was estimated as the ratio between the number of subjects fulfilling any criteria of the algorithm with better diagnostic accuracy and the total population in the same year (x 1,000), stratified by age, sex and district of residence. Results The two algorithms showed high accuracy for identifying patients with PD: one with greater sensitivity 94.2% (CI 88.4 – 97.6) and the other with greater specificity 98.1% (CI 97.7 – 98.5). For the estimation of prevalence, we chose the most specific algorithm with the fewest total number of misclassified cases. We identified 3,798 people with PD as of December 31, 2019 corresponding to a prevalence of 4.3 per 1,000 inhabitants (CI 4.2 – 4.4). Prevalence was higher in males (4.7, CI 4.5 – 5.0) than females (3.8, CI 3.7 – 4.0) and increased with age. The crude prevalence over time was slightly elevated as it followed a progressive ageing of the population. When stratifying the prevalence for age groups we did not observe a trend except in the 45-64 year category where we observed an increasing trend over time. Conclusion Algorithms based on administrative data are accurate when detecting people with PD in the Italian public health system. In a large northern Italian population, increased prevalence of about 10% was observed in the decade 2010-2019 and is explained by increased life expectancy. These data may be useful in planning the allocation of health care resources for people with PD.
DOI: 10.6084/m9.figshare.23884521
title: Supplementary Material for: Validation of administrative health data algorithms for identifying persons with Parkinson’s disease and the ten-year prevalence trend in Bologna, Italy

description: Introduction Health administrative databases are widely used for the estimation of the prevalence of Parkinson’s Disease (PD). Few in general, and none used in Italy, have been validated by testing their diagnostic accuracy. The primary objective was to validate two algorithms for the identification of persons with PD using clinical diagnosis as the reference standard on an Italian sample of people with PD. The second objective was to estimate 10-year trends in PD prevalence in the Bologna Local Health Trust from 2010 to 2019. Methods Two algorithms (index tests) applied to health administrative databases (hospital discharge, drug prescriptions, exemptions for medical costs) were validated against clinical diagnosis of PD by an expert neurologist (reference standard) in a cohort of consecutive outpatients. Sensitivity and specificity with relative 95% confidence intervals (CI) were calculated. The prevalence of PD in a specific year was estimated as the ratio between the number of subjects fulfilling any criteria of the algorithm with better diagnostic accuracy and the total population in the same year (x 1,000), stratified by age, sex and district of residence. Results The two algorithms showed high accuracy for identifying patients with PD: one with greater sensitivity 94.2% (CI 88.4 – 97.6) and the other with greater specificity 98.1% (CI 97.7 – 98.5). For the estimation of prevalence, we chose the most specific algorithm with the fewest total number of misclassified cases. We identified 3,798 people with PD as of December 31, 2019 corresponding to a prevalence of 4.3 per 1,000 inhabitants (CI 4.2 – 4.4). Prevalence was higher in males (4.7, CI 4.5 – 5.0) than females (3.8, CI 3.7 – 4.0) and increased with age. The crude prevalence over time was slightly elevated as it followed a progressive ageing of the population. When stratifying the prevalence for age groups we did not observe a trend except in the 45-64 year category where we observed an increasing trend over time. Conclusion Algorithms based on administrative data are accurate when detecting people with PD in the Italian public health system. In a large northern Italian population, increased prevalence of about 10% was observed in the decade 2010-2019 and is explained by increased life expectancy. These data may be useful in planning the allocation of health care resources for people with PD.
DOI: 10.6084/m9.figshare.23884524
title: Supplementary Material for: Validation of administrative health data algorithms for identifying persons with Parkinson’s disease and the ten-year prevalence trend in Bologna, Italy

description: Introduction Health administrative databases are widely used for the estimation of the prevalence of Parkinson’s Disease (PD). Few in general, and none used in Italy, have been validated by testing their diagnostic accuracy. The primary objective was to validate two algorithms for the identification of persons with PD using clinical diagnosis as the reference standard on an Italian sample of people with PD. The second objective was to estimate 10-year trends in PD prevalence in the Bologna Local Health Trust from 2010 to 2019. Methods Two algorithms (index tests) applied to health administrative databases (hospital discharge, drug prescriptions, exemptions for medical costs) were validated against clinical diagnosis of PD by an expert neurologist (reference standard) in a cohort of consecutive outpatients. Sensitivity and specificity with relative 95% confidence intervals (CI) were calculated. The prevalence of PD in a specific year was estimated as the ratio between the number of subjects fulfilling any criteria of the algorithm with better diagnostic accuracy and the total population in the same year (x 1,000), stratified by age, sex and district of residence. Results The two algorithms showed high accuracy for identifying patients with PD: one with greater sensitivity 94.2% (CI 88.4 – 97.6) and the other with greater specificity 98.1% (CI 97.7 – 98.5). For the estimation of prevalence, we chose the most specific algorithm with the fewest total number of misclassified cases. We identified 3,798 people with PD as of December 31, 2019 corresponding to a prevalence of 4.3 per 1,000 inhabitants (CI 4.2 – 4.4). Prevalence was higher in males (4.7, CI 4.5 – 5.0) than females (3.8, CI 3.7 – 4.0) and increased with age. The crude prevalence over time was slightly elevated as it followed a progressive ageing of the population. When stratifying the prevalence for age groups we did not observe a trend except in the 45-64 year category where we observed an increasing trend over time. Conclusion Algorithms based on administrative data are accurate when detecting people with PD in the Italian public health system. In a large northern Italian population, increased prevalence of about 10% was observed in the decade 2010-2019 and is explained by increased life expectancy. These data may be useful in planning the allocation of health care resources for people with PD.